Dimet-Wiley, Andrea L.
Latham, Christine M.
Brightwell, Camille R.
Neelakantan, Harshini
Keeble, Alexander R.
Thomas, Nicholas T.
Noehren, Haley
Fry, Christopher S.
Watowich, Stanley J.
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-19-1-0290, W81XWH-19-1-0290)
National Institutes of Health (1U44AG074107-01, 1U44AG074107-01, 1U44AG074107-01, 1U44AG074107-01, 1U44AG074107-01, 1U44AG074107-01, 1U44AG074107-01, 1U44AG074107-01, NIDDK 1R41DK119052-01)
Article History
Received: 2 February 2024
Accepted: 26 June 2024
First Online: 5 July 2024
Competing interests
: SJ Watowich is the Founder of Ridgeline Therapeutics; AL Dimet-Wiley and H Neelakantan are employees of Ridgeline Therapeutics. All other authors declare no conflicts of interest.